SMA Europe call for research projects
SMA Europe has announced its third international Call for SMA Research Projects, following the successful Calls in 2008 and 2009.
This third Call for SMA Projects will be open to any research project aimed at finding a cure or therapy for Spinal Muscular Atrophy (SMA). Priority will, however, be given to projects concentrating on the following aspects/fields: Basic research, Gene and/or Cell therapy, Clinical trials, Biomarkers and/or functional outcome measures and Drug development.
SMA Europe want this Call for Projects to foster both international collaboration between SMA researchers and to address potential bottlenecks in the search for cures and therapies for SMA. Preference may be given to applicants who address these concerns.
The screening of applications in 2010 will be provided by a scientific advisory board under the direction of AFM (Association Française Contre les Myopathies). If applicants need further information regarding the process or the make up of the selection panels, please contact AFM at sma-europe@afm.genethon.fr
The final choice of projects to be funded will be selected by the representatives of the partner organisations, based on the recommendations made by the advisory board.
SMA Europe has no central secretariat, and the selected projects will be allocated to member organisations of SMA Europe for funding. Contractual and financial responsibility for a project will be taken directly by the member organisation(s) on behalf of SMA Europe.
The application deadline for projects is 8th October 2010.
Two types of research grants will be awarded Operating Grants and Postdoctoral Fellowships.
It is anticipated that notification of Awards will be made early in 2011 with funding to commence as soon as possible thereafter, subject to contracts being agreed between the relevant parties. It is recognised that time lines will be affected by project specifics, notably in the case of potential part or joint funding of a clinical trial.
Full details can be downloaded from here.
